EGFR exon 20 mutant inhibitor, oral once-daily FDA-approved for EGFR ex20+ NSCLC from cellular screening + SBDD Bioorg. Med. Chem. Lett., 21 November 2022 ARIAD/Takeda, Cambridge, MA